CI stock forecast, quote, news & analysis

Key Takeaways

• CI stock declined -5.6% over the past 30 days amid CEO transition uncertainty and healthcare sector pressures, despite a recent analyst upgrade.
• Over the past quarter, shares fell -2.9%, reflecting broader market challenges in health insurance following muted 2026 guidance.
• Key drivers include leadership change at Cigna, PBM model shifts, regulatory scrutiny on the sector, and elevated medical cost trends.
• Strong Q4 2025 earnings provided a temporary lift, but investor sentiment remains cautious due to Evernorth segment headwinds.
• Bernstein's recent upgrade to Outperform highlights potential resilience in pharmacy benefits management amid reforms.

The Cigna Group (CI) Company Overview and Market Position

The Cigna Group (CI) is a global health company providing insurance, pharmacy benefit management (PBM), and specialty pharmacy services through its Cigna Healthcare and Evernorth Health Services segments. Its core business model focuses on employer-sponsored plans, government programs, and PBM operations serving health plans, employers, and the Department of Defense. In the competitive healthcare industry, Cigna holds a strong position via its integrated services, particularly Evernorth's scale post-Express Scripts acquisition. Recent stock behavior ties to its reduced Medicare Advantage exposure—sold in 2025—and reliance on commercial health and PBM growth, which face regulatory and cost pressures explaining the downward price movement.

The Cigna Group (CI) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, CI stock fell -5.6%, from approximately $282 around late February to $265.87 as of March 24, 2026. The decline was volatile, with a peak near $289 early March followed by a sharp drop to $260.87 mid-month, then partial recovery. This range-bound yet downward trend reflects event-driven swings.

For the past quarter, shares dropped -2.9%, starting around $274 in late December and fluctuating amid earnings and news. Movement was trend-driven lower post-February highs near $293, stabilizing recently but unable to regain prior levels amid sector headwinds.

What Drove CI Stock Price in the Last 30 Days

The 30-day decline stemmed primarily from the March 3 announcement of CEO David Cordani's retirement, with President and COO Brian Evanko succeeding him on July 1. Shares slipped around 5% premarket on the news, viewed as unexpected amid business model transitions, sparking leadership uncertainty. Broader healthcare pressures, including CMS enrollment halts in certain plans and Medicare Advantage retrenchment by peers, weighed on sentiment despite Cigna's limited MA exposure. Elevated medical costs and PBM rebate model changes added volatility. A counterpoint was Bernstein's March 12 upgrade to Outperform with a $358 target, citing PBM reform clarity and FTC settlement, aiding a rebound from lows.

What Drove CI Stock Performance Over the Last Quarter

The quarterly downturn reflected sustained sector challenges, amplified by Cigna's Q4 2025 earnings on February 5. While adjusted EPS of $8.08 beat estimates and revenue hit $72.5 billion—driven by Evernorth growth—2026 guidance of at least $30.25 EPS and $280 billion revenue trailed Wall Street hopes, pressuring shares post-initial gains. PBM headwinds from rebate-to-discount shifts, flagged in prior quarters, persisted into 2026 projections. Macro factors like rising medical loss ratios (83.7%-84.7% outlook), regulatory scrutiny including FTC insulin settlement and House subpoenas, and healthcare peers' MA profit squeezes contributed cumulatively. Institutional focus on Evernorth's trajectory amid reforms dominated, outweighing full-year 2025 beats.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots from hundreds available, which analyze and trade thousands of tickers across various markets. These curated bots highlight those with the strongest recent performance, relevance to current market trends, and diverse strategies such as trend-following, mean reversion, or momentum plays. Timeframes range from intraday to long-term holds, with key metrics like win rate, profit factor, and drawdown displayed for transparency. Users can explore, backtest, and deploy these bots to automate trading decisions. For investors seeking data-driven stock analysis and price movement insights, visit the Trending AI Robots page to discover tools tailored to optimize portfolios amid volatile market trends.

CI Stock Forecast Drivers: What Investors Should Watch Next

Investors should monitor Cigna's Q1 2026 earnings for updates on Evernorth growth and medical cost trends. Upcoming leadership transition to Brian Evanko in July could influence strategic execution on PBM reforms. Regulatory developments, including PBM legislation impacts, FTC follow-ons, and CMS Medicare policies, remain critical despite limited MA reliance. Sector dynamics like peer MA enrollment shifts and inflation-driven utilization bear watching. Potential catalysts include new contracts or specialty pharmacy expansions; risks encompass rising loss ratios, competitive pressures, and macroeconomic shifts in rates or demand.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations